Rudin D
Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
ArticleMDMA
Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study.
ArticlePsilocybin
Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.
ArticlePsychedelics
The 4-alkyl chain length of 2,5-dimethoxyamphetamines differentially affects in vitro serotonin receptor actions versus in vivo psychedelic-like effects.
ArticleMDMA
Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants.
ArticleLSD
Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study.
ArticlePsilocybin
Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.
ArticleDMT
Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants.
ArticleMDMA
Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants.
ArticlePsilocybin
<i>In vitro</i> and <i>in vivo</i> metabolism of psilocybin's active metabolite psilocin.
ArticleDMT
Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants.
ArticlePsilocybin
Classic psychedelics do not affect T cell and monocyte immune responses.
ArticleMDMA